Target intelligence / Profile preview

Calcium homeostasis modulator protein 2 (CALHM2)

Target
CALHM2
Molecular classification
Ion channel, Large-pore channel, Membrane protein
01

Overview

Calcium homeostasis modulator protein 2 (CALHM2) is a membrane-bound, large-pore ion channel belonging to the CALHM family. It forms oligomeric assemblies, typically as an 11-mer, and is predicted to enable monoatomic cation channel activity. CALHM2 mediates ATP release from astrocytes and regulates ATP-induced Ca²⁺ influx in microglia, modulating neuronal ATP and calcium homeostasis, synaptic transmission, and neuroinflammatory responses. The protein may also form intercellular gap junction-like structures and is implicated in the regulation of apoptosis. CALHM2 is expressed in the central nervous system—especially in glial cells—and linked to the pathophysiology of depression and neurodegenerative diseases such as Alzheimer's disease, with emerging associations to medulloblastoma. Channel gating mechanisms remain incompletely understood, and aside from a report of inhibition by rubidium red, specific drugs targeting CALHM2 are lacking[1][2][3].

Other names
FAM26BProtein FAM26BCalcium homeostasis modulator 2Calcium homeostasis modulator family member 2Family with sequence similarity 26, member B
02

Mechanism of action

Channel inhibition (for rubidium red; other mechanisms currently unknown due to lack of further identified drugs)[1]

03

Biological functions

Ion transport (monoatomic cation channel activity)ATP release from astrocytesRegulation of ATP-induced Ca²⁺ influx in microgliaRegulation of neuronal ATP and calcium homeostasisModulation of synaptic transmissionNeuroinflammatory responsePositive regulation of apoptotic processes
04

Disease associations

Neurodegenerative disease (implicated in Alzheimer’s disease pathophysiology)Depression (CALHM2 linked to glial-neuronal function and mood regulation)Cancer (associate with medulloblastoma as per gene-disease annotation)Other (possible roles in taste perception, but more certain for other CALHM family members)
05

Safety considerations

No specific safety concerns identified in current sources; large-pore channels in general may modulate cell death or cell signaling, which could pose toxicity challenges if targeted systemically[3]
06

Interacting drugs

Rubidium red (identified as a putative inhibitor in structural studies)[1]
07

Biomarkers

No validated biomarkers identified in current sources

Beyond the preview

Go deeper on Calcium homeostasis modulator protein 2 (CALHM2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Calcium homeostasis modulator protein 2 (CALHM2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call